このエントリーをはてなブックマークに追加


ID 64117
JaLCDOI
フルテキストURL
76_6_673.pdf 1.96 MB
著者
Okazawa-Sakai, Mika Department of Clinical Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Yamamoto, Yasuko Department of Cancer Genomic Medicine, National Hospital Organization Shikoku Cancer Center
Futagawa, Mashu Department of Clinical Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Okamura, Miki Department of Hereditary Tumors, National Hospital Organization Shikoku Cancer Center
Miyawaki, Satoko Department of Cancer Genomic Medicine, National Hospital Organization Shikoku Cancer Center
Nishina, Tomohiro Department of Cancer Genomic Medicine, National Hospital Organization Shikoku Cancer Center
Takehara, Kazuhiro Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center
Kozuki, Toshiyuki Department of Clinical Research Center, National Hospital Organization Shikoku Cancer Center
Tomida, Shuta Center for Comprehensive Genomic Medicine, Okayama University Hospital
Hyodo, Ichinosuke Department of Cancer Genomic Medicine, National Hospital Organization Shikoku Cancer Center
Ohsumi, Shozo Department of Hereditary Tumors, National Hospital Organization Shikoku Cancer Center
Hirasawa, Akira Department of Clinical Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
抄録
Patients found to have presumed germline pathogenic variants (PGPVs) during comprehensive genomic profiling (CGP) require genetic counseling (GC) referrals. We retrospectively investigated the outcomes of patients with PGPVs. Among 159 patients who underwent CGP, we recommended GC for the 16 patients with PGPVs (3 with [FG group] and 13 without [G Group] a family/personal history of hereditary cancer) as well as for the 8 patients with no PGPVs, but a history (F group); 2 (67%), 5 (38%), and 3 (38%) patients received GC in the FG, G, and F groups, respectively. Germline testing results were positive in 1 and 2 patients of the FG and G groups, respectively. Among the patients recommended for GC, 58% did not receive GC due to lack of interest, poor performance status, or death. CGP contributes to the identification of germline variants in patients without a history of hereditary cancer. However, the proportion of patients who undergo GC should be improved.
キーワード
comprehensive genomic profiling
hereditary cancer
germline findings
presumed germline pathogenic variant(s)
genetic counseling
Amo Type
Original Article
出版物タイトル
Acta Medica Okayama
発行日
2022-12
76巻
6号
出版者
Okayama University Medical School
開始ページ
673
終了ページ
678
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
英語
著作権者
Copyright Ⓒ 2022 by Okayama University Medical School
論文のバージョン
publisher
査読
有り
PubMed ID
Web of Science KeyUT